相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
常温,避光
- 克隆性:
单克隆
- 抗体名:
VEGF 183 / VEGF-A抗体
Antibody Type : Rabbit Polyclonal Antibody ( Antibody Purification Platform )
抗体宿主 : Rabbit IgG
缓冲液 : 0.2 μm filtered solution in PBS, 5% trehalose may be added in some batches. Please read the hardcopy of COA or contact our customer service to confirm the formulation.
制备方法 : Produced in rabbits immunized with purified, recombinant Human VEGF 183 / VEGF-A (rh VEGF 183 / VEGF-A; Catalog#10009-HNAB; P15692-3; Met 1-Arg 209). VEGF 183 / VEGF-A specific IgG was purified by Human VEGF 183 / VEGF-A affinity chromatography.
VEGF 183 / VEGF-A抗体 Background
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. It is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and often exists as a disulfide-linked homodimer. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. As its name implies, VEGF-A activity has been mostly studied on cells of the vascular endothelium, although it does have effects on a number of other cell types (stimulation monocyte/macrophage, neurons, cancer cells, kidney epithelial cells). VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor. Alternatively spliced transcript variants of VEGF-A, encoding either secreted or cell-associated isoforms, have been identified. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans.
VEGF 183 / VEGF-A抗体相关产品如下:xy-1146xy N-ras原癌基因抗原
xy-1074xy Nrf2 peptide核因子2相关因子2抗原
xy-1342xy NRF-1(nuclear respiratory factor-1)核呼吸因子-1抗原
xy-1958xy NTCP(Na+/taurocholate Cotransporting Polypeptide)钠离子/牛磺胆酸共转运蛋白抗原
xy-1375xy Ghrelin 28脑肠肽28
xy-1495xy OCLN(Occluding)咬合蛋白抗原
xy-1111xy Oct-4(Octamer-4)胚胎干细胞关键蛋白抗原
xy-1294xy ODC(Ornithine decarboxylase)鸟氨酸脱羧酶抗原
xy-2086xy ompF(putative outer membrane porin F protein)小肠结肠炎耶尔森氏菌膜通道蛋白抗原
xy-2173xy OLFM1 peptide嗅球蛋白1多肽抗原
xy-1181xy ORX-A(orexin-A)增食欲素-A/欲激素A抗原
xy-1314xy OTR(oxytocin receptor)缩宫素受体
xy-1095xy OXR (Orexin receptor)食欲素受体(多肽)
xy-1483xy P2P-R/RBBP6(proliferation potential protein related)增殖潜能相关蛋白抗原
xy-0534xy P19ARFp19ARF抑癌基因抗原
xy-2210xy phospho-p38 ERK/MAPK14 (pThr180/pTyr182) peptide磷酸化丝裂原活化蛋白激酶p38抗原
xy-1689xy MKK3(MAP Kinase Kinase 3)丝裂原活化蛋白激酶MKK3/6抗原
xy-2090xy P53(wt-p53)肿瘤抑制基因抗原(野生型P53)
xy-0913xy Mtp53(Mutant type p53)突变型P53抗原
xy-0942xy WIG-1(wtp53-induced gene 1)野生型p53诱导基因1抗原
xy-1346xy P73 proteinP73肿瘤抑制基因抗原
xy-1426xy p70 S6 Kinase/P70 Beta1p70S6Kb抗原
xy-0588xy PALB2(partner and locaizer of BRCA2)乳腺癌易感基因相关蛋白2
xy-1478xy PAFR/PTAFR血小板活化因子受体抗原
xy-2270xy Phospho-PAK4 (Ser99) peptide磷酸化p21激活激酶4多肽抗原
xy-0655xy PAK7/PAK5/MBT激活激酶PAK7/PAK5抗原
xy-0828xy PAR-1 (Protease-activated receptors-1)蛋白酶激活受体-1抗原
xy-1178xy PAR-2 (Protease-activated receptors-2)蛋白酶激活受体-2抗原
xy-1196xy PAR4 (protease-activated receptor 4)蛋白酶活化受体4/前列腺细胞凋亡反应蛋白4抗原
xy-2138xy PARP(poly ADP-ribose polymerase)N-Terminus多腺苷二磷酸多聚酶抗原(N端)
xy-1201xy PAX8(Paired box gene 8)配对盒基因8抗原
xy-1102xy PAX9(Paired box gene 9)配对盒基因9抗原
xy-1159xy P-cadherin(placental)P-钙粘附分子抗原
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【求助】求助VEGF and Tenascin and Aggrecan
jellyfish102 Tenascin和Aggrecan与VEGF之间是什么关系,Tenascin和Aggrecan是VEGF的下游基因吗,课题需要,请专家答疑,谢谢。 chuckdouble 不是专家的个人意见 首先, 是否***因子是***因子的上游或下游 这种问题, 需要具体到哪种模型, 哪种细胞, 哪种亚型. 不然一般不存在答案. tenascin 是个家族, 有 TNC
Science:延长小鼠寿命 50%!提升 VEGF 水平可
粥样硬化等心血管疾病,并且其发病率随年龄增长而增加。因此,对抗血管衰老也可能是一种有效的缓解机体衰老的策略。血管内皮生长因子(VEGF)可在许多成人组织中产生,是一种具有血管相关功能和非血管功能的高度多效生长因子,除了血管生成活性,VEGF 还在控制血管通透性、维持新形成血管的存活、维持器官特异性血管特征等方面发挥重要作用。既往研究表明,改善 VEGF 信号通路可影响肝脏再生和骨骼肌的运动能力,但 VEGF 是否参与衰老以及其与衰老相关生物学特征之间的关系仍然是未知的。2021 年 7 月 30 日,以色列
dscgu 迄今已发现了VEGF的三种酪氨酸蛋白激酶受体,分别是VEGFR-1(flt-1)、VEGFR-2(flk-1,也称KDR)、VEGFR-3(flt-4)。 是否能选择性抑制VEGFR-1(flt-1)、VEGFR-2(flk-1,也称KDR)、 freecell ZM323881, a VEGF receptor (Flk-1)-specific inhibitor http://www.ncbi
技术资料暂无技术资料 索取技术资料




